Drew Ranieri
Stock Analyst at Morgan Stanley
(1.26)
# 3,443
Out of 4,749 analysts
163
Total ratings
46.07%
Success rate
-13.43%
Average return
Main Sectors:
Stocks Rated by Drew Ranieri
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GMED Globus Medical | Upgrades: Overweight | $83 → $100 | $92.72 | +7.85% | 12 | Dec 2, 2024 | |
| SYK Stryker | Upgrades: Overweight | $370 → $445 | $391.29 | +13.73% | 9 | Dec 2, 2024 | |
| SIBN SI-BONE | Maintains: Overweight | $21 → $19 | $16.76 | +13.37% | 15 | Aug 6, 2024 | |
| IART Integra LifeSciences Holdings | Maintains: Underweight | $24 → $27 | $26.10 | +3.45% | 15 | Jul 15, 2024 | |
| TMCI Treace Medical Concepts | Maintains: Equal-Weight | $5.5 → $8 | $10.05 | -20.40% | 12 | Jul 15, 2024 | |
| STVN Stevanato Group | Maintains: Equal-Weight | $26 → $22 | $22.41 | -1.83% | 16 | Jul 15, 2024 | |
| NPCE NeuroPace | Maintains: Equal-Weight | $9.5 → $8 | $13.76 | -41.86% | 13 | Jul 15, 2024 | |
| ATEC Alphatec Holdings | Maintains: Overweight | $19 → $16 | $11.79 | +35.71% | 8 | Jul 15, 2024 | |
| OM Outset Medical | Maintains: Equal-Weight | $5 → $5.5 | $0.80 | +587.50% | 10 | Dec 4, 2023 | |
| ORGO Organogenesis Holdings | Maintains: Equal-Weight | $3 → $3.5 | $3.68 | -4.89% | 3 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $38 | $20.52 | +85.19% | 9 | Nov 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $88 → $96 | $69.05 | +39.03% | 10 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $28 → $26 | $17.22 | +50.99% | 8 | May 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $290 → $295 | $247.60 | +19.14% | 2 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $236 → $280 | $180.24 | +55.35% | 5 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $5 | $10.68 | -53.18% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $70 | $32.56 | +114.99% | 4 | Oct 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $325 → $300 | $571.88 | -47.54% | 6 | Apr 25, 2022 |
Globus Medical
Dec 2, 2024
Upgrades: Overweight
Price Target: $83 → $100
Current: $92.72
Upside: +7.85%
Stryker
Dec 2, 2024
Upgrades: Overweight
Price Target: $370 → $445
Current: $391.29
Upside: +13.73%
SI-BONE
Aug 6, 2024
Maintains: Overweight
Price Target: $21 → $19
Current: $16.76
Upside: +13.37%
Integra LifeSciences Holdings
Jul 15, 2024
Maintains: Underweight
Price Target: $24 → $27
Current: $26.10
Upside: +3.45%
Treace Medical Concepts
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $5.5 → $8
Current: $10.05
Upside: -20.40%
Stevanato Group
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $26 → $22
Current: $22.41
Upside: -1.83%
NeuroPace
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $9.5 → $8
Current: $13.76
Upside: -41.86%
Alphatec Holdings
Jul 15, 2024
Maintains: Overweight
Price Target: $19 → $16
Current: $11.79
Upside: +35.71%
Outset Medical
Dec 4, 2023
Maintains: Equal-Weight
Price Target: $5 → $5.5
Current: $0.80
Upside: +587.50%
Organogenesis Holdings
Nov 14, 2023
Maintains: Equal-Weight
Price Target: $3 → $3.5
Current: $3.68
Upside: -4.89%
Nov 2, 2023
Maintains: Overweight
Price Target: $42 → $38
Current: $20.52
Upside: +85.19%
May 12, 2023
Maintains: Equal-Weight
Price Target: $88 → $96
Current: $69.05
Upside: +39.03%
May 4, 2023
Maintains: Underweight
Price Target: $28 → $26
Current: $17.22
Upside: +50.99%
Feb 3, 2023
Maintains: Overweight
Price Target: $290 → $295
Current: $247.60
Upside: +19.14%
Jan 6, 2023
Maintains: Equal-Weight
Price Target: $236 → $280
Current: $180.24
Upside: +55.35%
Nov 10, 2022
Maintains: Overweight
Price Target: $11 → $5
Current: $10.68
Upside: -53.18%
Oct 11, 2022
Maintains: Overweight
Price Target: $72 → $70
Current: $32.56
Upside: +114.99%
Apr 25, 2022
Maintains: Equal-Weight
Price Target: $325 → $300
Current: $571.88
Upside: -47.54%